GSK submits landmark IMPACT data to FDA to support expanded label for Trelegy Ellipta
GlaxoSmithKline and Innoviva announced the filing of a sNDA with the FDA for use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI') for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. November 23, 2017